A phase I trial of mFOLFOX6 and the oral PI3K inhibitor BKM120 in patients with advanced solid tumors (4/17 CCA) reported high toxicity rates, with 76 % of the patients experiencing a grade 3/4 AE [75]. The gene discussed is PIK3CA; the disease is cholangiocarcinoma.